Loading news...
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $27.92 and last traded at $27.1690, with a volume of 109492 shares. The stock had previously closed at $27.05. The company
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
SG Americas Securities LLC raised its stake in Immunovant, Inc. (NASDAQ: IMVT) by 679.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,598 shares of the company's stock after purchasing an additional 54,570 shares during the quarter. SG
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Northwest Biotherapeutics and
The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Stock News Ford pivots from full EV to hybrids and storage: Ford Motor (F) will discontinue the allâelectric Fâ150 Lightning and replace it with a plugâin
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.